The objectives of this study were to determine the effects of ractopamine HCl (RAC) stereoisomers (RR, RS, SR, and SS) on performance, carcass composition, and nitrogen retention in growing female rats. Forty-eight rats (eight rats/treatment) were treated with 0 or 320 mg/d of RAC or with 80 mg/d of the RR, RS, SR, or SS stereoisomers of ractopamine. Rats had free access to feed and water before and during the experiment. Ractopamine and stereoisomers were delivered via i.p. implanted osmotic pumps for 14 d, and rats were then slaughtered. Control rats were fitted with osmotic pumps containing saline. Ractopamine increased ( P < .05) feed intake ( d 1 to 6); body weight; carcass CP; and intake, apparent absorption, retention, and retained:intake ratio of CP on d 1 to 6 of the study. Ractopamine decreased ( P < .05) carcass lipid and visceral lipid. Rats dosed with the RR stereoisomer responded similarly to rats dosed with RAC, except for carcass lipid. Carcass lipid was decreased ( P < .01) by RAC relative to controls, but it was not different from controls in rats treated with the RR isomer. Compared with controls, BW, carcass CP, and CP retention were increased by the RR stereoisomer, and visceral lipid was decreased. The RS isomer also decreased visceral lipid ( P < .10), but variables measured in rats dosed with the RS, SR, and SS isomers generally did not differ from controls. Results of this study indicate that the RR isomer of RAC is responsible for a majority of the leanness-enhancing effects of RAC in rats.
Introduction
Phenethanolamine b-adrenergic agonists are, by definition, chiral compounds. That is, molecular asymmetry exists at the hydroxylated carbon b-to an aliphatic nitrogen and a-to a substituted benzyl group common to all phenethanolamine b-agonists ( Figure  1) . On a practical level, this means that most commercial phenethanolamine drugs are mixtures of stereoisomers unless stereospecific synthetic or purification techniques are used during their manufacture. Cimaterol (U.S. Pharmacopeia, 1997) , clenbuterol (Abou-Basha and Aboul-Enein, 1996) , ractopamine (U.S. Pharmacopeia, 1997) , salbutamol (Aboul-Enein et al., 1981) , and zilpaterol (U.S. Pharmacopeia, 1997) are leanness-enhancing agents Casey et al., 1997a,b) that are stereoisomeric mixtures. To our knowledge, the only leannessenhancing b-agonist that was developed as a single stereoisomer and tested in livestock is L-644,969 .
For direct-acting phenethanolamine b-adrenergic agonists, biologically active stereoisomers are levorotatory. Dextrorotatory stereoisomers are either inactive or are considerably less potent than the levorotatory isomer (Ruffolo, 1991) . There are few data published regarding the leanness-enhancing effects of b-adrenergic agonist stereoisomers.
Ractopamine HCl ( RAC; Figure 1 ) is a phenethanolamine b-adrenergic agonist that contains two chiral carbons and exists as a mixture of four stereoisomers (Smith et al., 1993; U.S. Pharmacopeia, 1997) . Our objectives for this study were to determine the effects of individual ractopamine stereoisomers on growth rate, protein retention, and body composition of growing rats. 
Materials and Methods

Synthesis of Ractopamine HCl Stereoisomers
Stereoisomers of ractopamine HCl were prepared as described by Anderson et al. (1987 Anderson et al. ( , 1988 with several modifications. d,l-1-Methyl-3-(4-benzyloxyphenyl)propyl amine was prepared from methyl-2-(4-benzyloxyphenyl) ethyl ketone via its oxime. Hydroxylamine HCl (191.8 g, 2.76 mol) was refluxed for 2 h with 350 g (1.38 mol) of the ketone in 1.5 L of methanol and 500 mL of pyridine. Approximately onehalf of the solvents were removed by distillation, and 400 mL of water was added. The solution was cooled, and 373 g of product was collected by filtration; melting point ( m.p.) was 130 to 136°C. The crude oxime (269 g, 1 mol) was dissolved in 1 L of dry tetrahydrofuran ( THF) and added slowly to a suspension of 100 g of lithium aluminum hydride in 1 L of THF. After the addition was completed, the mixture was refluxed for 1 h, cooled, and the complex was decomposed by the slow addition of 250 mL of water. The solution was filtered, the solvents were removed, and the residue was distilled at .05 torr (6.67 Pa) to yield 180 g of d,l-1-methyl-3-(4-benzyloxyphenyl) propyl amine. The S isomer of the amine was resolved by reaction with an equimolar amount of ( S ) -( + ) mandelic acid and recrystalized from methanol: m.p. 170 to 172°C, [a] D +31.73. The solvent was removed from the mother liquor, the resulting solid was converted to the free base, and it was reacted with ( R ) -( −) mandelic acid. Recrystalization from methanol yielded the R isomer: m.p. 170 to 173°C, [a] D −31.59.
The borane-dimethyl sulfide reaction described in the patent literature proved to be troublesome. Formation of the des-hydroxyl compound (dehydrated at the benzylic carbon) was consistently observed but was formed to a variable extent depending on the reaction. Rate of addition and temperature during borane-dimethyl sulfoxide addition did not correlate with the extent of formation. The des-hydroxyl compound could be removed by recrystallization, albeit with a considerable loss of product. Removal of the des-hydroxyl compound at this stage was vital because ractopamine stereoisomers could not be recrystallized from the des-hydroxyl compound after the debenzylation step. Samples of ractopamine stereoisomers that were contaminated with the des-hydroxyl compound could be purified using preparative HPLC with C-18 packing and an isocratic mobile phase consisting of 84% .05 M NaCl and 16% CH 3 CN.
The hydrochloride salt of the ractopamine stereoisomers could be prepared by the addition of ethereal hydrogen chloride (an excess of acid would result in decomposition) or by the addition of an excess of 2.5 N HCl and removal of water and excess acid by freeze-drying. The following specific rotations [a] 25 D were obtained in methanol: RR, −22.0; SS, +21.3; RS, −47.0; and SR, +45.0. The specific rotation of the des-hydroxyl formed in the RR preparation was +5.5; thus, small amounts of this impurity would significantly affect the specific rotation of the final product.
Chemical identities of the individual stereoisomers were confirmed using 1 H-and 13 C-nuclear magnetic resonance spectroscopy, (+)-ion fast atom bombardment mass spectrometry, Fourier-transformed infrared spectroscopy, and optical rotation.
Determination of Stereochemical Purity
Stereochemical purities of individual ractopamine HCl stereoisomers were determined by derivatization with [ ( 4 S-cis)-2,2-dimethyl-5-isothiocyanato-4-phenyl-1,3-dioxane; PHEDIT] followed by reversephase HPLC. The PHEDIT reagent was synthesized as described by Desai and Gal (1992) . Individual stereoisomers of ractopamine HCl were dissolved in methanol ( 2 mg/mL), and 500-mL aliquots of each stereoisomer were transferred to conical glass reaction vessels. Methanol was evaporated using a centrifugal evaporator (Savant Instruments, Farmingdale, NY), and the residue was dissolved in 100 mL of a water: acetonitrile:triethylamine (50:50:3) solution. Each reaction vessel was capped, placed on a block heater, and heated to 60°C. After the reaction vials had reached 60°C, 50 mL of a 60 mg/mL solution of the PHEDIT reagent (dissolved in acetonitrile) was added to each vial. After a 30-min reaction period, reactions were removed from the heating block and diluted with 400 mL of acetonitrile. Chromatographic analysis was conducted as described by Smith et al. (1995) .
Ractopamine Stereoisomer Study
Seventy 100-g female Sprague-Dawley rats (Harlan Sprague-Dawley, Madison, WI) were housed in individual stainless steel cages. Daily body weights were measured and recorded. Rats were provided ad libitum access to feed and water for 7 d and were housed under a 12 h light-dark cycle. Diets consisted of ground (2-mm screen) rat chow (Purina Rat Chow no. 5012, Purina Mills, St. Louis, MO; CP ≥ 22%, fat ≥ 4%, crude fiber ≤ 5%, ash ≤ 8%, and added minerals ≤ 8%). Forty-eight rats were selected based on uniformity relative to a target body weight of 150 g and were randomly assigned to six treatments: control ( C) , ractopamine ( RAC) , or RR, RS, SS, or SR stereoisomers of RAC. Control rats were implanted with mini-osmotic pumps containing sterile saline.
Surgical techniques were approved by the Institutional Animal Care and Use Committee and followed the procedure outlined by Smith and Paulson (1994) . Mini-osmotic pumps implanted into the RAC-treated rats contained 26.7 mg/mL of RAC; mini-osmotic pumps implanted into the RR-, RS-, SR-, and SS-treated rats contained 6.7 mg/mL of the RR, RS, SR, and SS stereoisomers, respectively. The target dose for RACtreated rats was 320 mg/d and was 80 mg/d for the RR, RS, SR, and SS stereoisomer-treated rats.
Rats were surgically implanted with mini-osmotic pumps designed to release .5 mL/h (Alzet model 2002; 226 mL mean fill volume; Alza, Palo Alto, CA). Rats were anesthetized with 5% halothane in O 2 ( 1 L/min) and nitrous oxide ( 1 L/min). Anesthesia was maintained using 2.5% halothane; nitrous oxide and O 2 delivery rates were reduced to .4 L/min. Osmotic pumps were implanted as described by Smith and Paulson (1994) . Two rats died during surgery because of over-anesthesia, but they were replaced with preselected substitute rats. Surgical implantation of the pumps into the remaining rats was unremarkable.
Immediately after completion of implantation of the mini-osmotic pumps, rats were placed in individual metabolism cages designed to allow for the separate collection of urine and feces. Urine was collected into 50-mL conical tubes containing 1 mL of 6 N HCl. Urine and feces were gathered every 48 h and kept frozen until they were analyzed. Rats were given ad libitum access to feed and water during the study period, and all rats completed the study. On d 14 of the study, rats were killed by asphyxiation with CO 2 and were immediately dissected to remove the osmotic pumps and to separate the carcass from the viscera. Viscera consisted of the gastrointestinal tract, intraperitoneal adipose tissue, pancreas, and spleen. Carcasses consisted of head, hide, bone, tail, muscle, heart, lungs, kidneys, liver, and reproductive tracts. Viscera and carcasses were placed in labeled bags and kept frozen until they were analyzed.
Frozen carcasses were individually ground through an electric meat grinder two times and mixed thoroughly. Carcasses were refrozen and lyophilized. Dried carcasses were blended to uniformity using a Waring blender. Viscera were blended to a slurry in a Waring blender, frozen, and then lyophilized.
Fecal samples were dried at 50°C in a drying oven overnight and then allowed to cool. Fecal samples were combined so that samples collected on d 1 to 6 and 7 to 12 were pooled within each rat. Pooled fecal samples were then ground through a 2-mm screen and were stored. Duplicate fecal and carcass samples were dried in a 100°C drying oven to determine dry matter (AOAC, 1990; method 950.46) . Viscera data are expressed on a dry matter basis obtained from lyophilization.
Lipid content of carcasses and gastrointestinal tracts was determined by Soxhlet extraction (AOAC, 1990; method 960.39) . Feces, gastrointestinal tracts, and carcasses were analyzed for CP according to AOAC (1990; method 981.10) . Urine samples were pooled as described for feces and analyzed for CP as described by AOAC (1990; method 981.10) .
Verification of RAC release from the pumps was accomplished by placing primed pumps in 170 mL of continuously stirred physiological saline and determining the appearance of RAC in the saline over time by HPLC. One-milliliter samples of the contents of each vial were removed daily and frozen prior to analysis by HPLC. Tandem Nova-Pak C-18 HPLC columns (100 × 8 mm; Waters Associates, Milford, MA) were attached to Gilson (Middleton, WI) pumps and a Gilson ultraviolet detector set at 254 nm. The RAC was eluted from the column using a mobile phase consisting of .05 M ammonium acetate (pH 4.5) and acetonitrile. Acetonitrile was increased linearly from 5 to 25% of the mobile phase during the 40-min chromatographic run.
Data were analyzed as a completely randomized design. Significant F-tests served as an indication to separate means using the method of least significant difference (Cochran and Cox, 1957) .
Results
Syntheses
Adequate quantities of each stereoisomer were chemically synthesized with difficulty. Loss of product and purity in the borane reduction and debenzylation steps hampered the efficacy of the reaction. Final chemical purity of each stereoisomer was greater than 97% as assessed by HPLC, and stereochemical purity of each isomer was greater than 98%.
Stereoisomer Growth Trial
Feed intake (Table 1 ) was increased ( P < .02), relative to controls, by RAC and by the RR stereoisomer during d 1 to 6, but feed intake was not altered by either RAC or any of the stereoisomers during d 7 to 12 of the growth trial. When feed intake was expressed as a percentage of BW, no treatment differences were observed over the entire study. Live BW was increased ( P < .07) by RAC and the SR stereoisomer during d 1 to 6 of the study, but by d 12 only the RAC and RR treatments had caused significant ( P < .02) increases compared to controls. Neither RAC nor individual stereoisomers increased the efficiency of feed utilization for d 1 to 6 or d 7 to 12 of the study relative to controls, although this variable was greater ( P < .09) for the RAC and RR treatments than for the SR and SS treatments on d 1 to 6. No treatment effects were observed for ADG or net BW gain during d 1 to 6 or 7 to 12 relative to controls. During d 1 to 6, the ADG and BW gain were greater for RAC treatments than for the RS, SR, or SS stereoisomers. Table 2 shows the effects of RAC and individual ractopamine stereoisomers on body composition of rats. No differences among treatments were observed for gross body weight ( d 14), carcass weight, or visceral weight. Carcass CP was increased ( P < .01) by the RAC and RR stereoisomer treatments. The RS, SR, and SS stereoisomers had no effect on carcass protein. Carcass lipid content (Soxhlet extraction) was decreased by RAC ( P < .01), but not by any of the stereoisomers. Visceral crude protein was not affected by treatment. Visceral lipid content, however, was substantially reduced ( P < .01) by RAC and the RR and RS stereoisomers. There was no effect of either the SR or SS stereoisomers of ractopamine on visceral lipid.
Effects of RAC and of ractopamine stereoisomers on CP retention of rats are shown in Table 3 . Crude protein intake was increased on d 1 to 6 by RAC compared to controls ( P < .02). There were no treatment effects on CP intake on d 7 to 12 of the study. Urinary and fecal CP excretion were not affected by treatment. Apparent CP absorption was increased ( P < .03) by RAC and the RR stereoisomer during the initial 6 d of the study but was not affected ( P > .83) on d 7 to 12. Retention of CP was also increased ( P < .10) by the RAC and RR treatments compared to the other treatments during the initial 6 d of the study, but, similar to CP absorption, it was not affected on d 7 to 12. Efficiency of CP utilization was also increased by RAC and the RR stereoisomer during the initial 6 d of the study but was not influenced by treatment during d 7 to 12. There were no treatment effects on the efficiency of CP absorption for either the 1-to 6-or 7-to 12-d study periods.
Discussion
b-Adrenergic agents generally promote increased rates of weight gain, efficiency of feed utilization, carcass leanness, and dressing percentage of test animals . Data from this study are in agreement with those of Smith and Paulson (1994) indicating that i.p. administered ractopamine HCl is effective at increasing the growth performance of rats. Additionally, results from dose titration trials conducted at our laboratory indicate that ractopamine HCl increases carcass leanness in rats (unpublished observations). These results are consistent with the effects of b-adrenergic "repartitioning" or leannessenhancing agents in other species.
Performance data (feed intake, BW, and gain:feed) have indicated that significant responses in rats were likely to occur at RAC levels at 320 mg/d (Smith and Paulson, 1994) . In swine, significant improvements in gain:feed are observed at levels as low as 5 ppm of dietary RAC, but significant effects on feed intake were not observed until dietary RAC was at 20 ppm (Watkins et al., 1990) . As discussed by Smith and Paulson (1994) , a dietary level of 20 ppm of RAC for rats the size used in this study represents an oral equivalent of roughly 320 mg RAC per day assuming a feed intake of roughly 16 g/d.
In contrast to results from Smith and Paulson (1994) , RAC-treated rats in this study did not have increased ADG relative to controls; however, BW was increased by RAC. In swine, ADG is not consistently increased by RAC. Bark et al. (1992) and Watkins et al. (1990) observed significant improvements in ADG with dietary RAC, but Yen et al. (1990) and Aalhus et al. (1990) did not. In turkeys, Wellenreiter and Tonkinson (1990) observed significant increases in weight gain after treatment with 11, 22, or 44 ppm of dietary RAC.
Carcass lipid was reduced, and carcass CP was increased by RAC, consistent with its leannessenhancing effects in other species (Bergen et al., 1989; Anderson et al., 1990; Dunshea et al., 1998) . In addition, RAC reduced visceral lipid in rats. Effects of RAC on visceral lipid have been measured in a diversity of species, and the effect in rats is not unique. For example, RAC reduced mesenteric fat in catfish (Mustin and Lovell, 1993) and decreased the proportion of leaf fat in swine (Adeola et al., 1990; Watkins et al., 1990 ), but did not reduce kidney, pelvic, and heart fat in feedlot steers (Carroll et al., 1990) .
Collectively, the performance, body composition, and nitrogen retention data are consistent with the hypothesis that the RR stereoisomer of RAC is responsible for its leanness-enhancing effect in rats. Such results are consistent with the report by Ruffolo (1991) indicating that for direct-acting b-adrenergic agonists the levorotatory stereoisomer is responsible for biological effects. Both the RR and RS stereoisomers of ractopamine HCl are levorotatory, suggesting that each of these isomers might be active, or that a combination of the two isomers might be necessary for biological activity. The RR stereoisomer mimicked the effect of RAC on feed intake, body weight, carcass CP, visceral lipid, apparent CP absorption, CP retention, and retained CP:intake CP.
The RS stereoisomer had significant effects on reducing visceral lipid content but did not mimic the effects of RAC for any of the other variables. Nevertheless, the reduction in carcass lipid of the RS stereoisomer might be expected because the RS isomer is levorotatory. In addition, the RS isomers of phenethanolamine b-adrenergic agonists closely related to ractopamine were lipolytic in mice (Yen et al., 1983 (Yen et al., , 1989 and reduced the accumulation of body fat in rats (Shaw et al., 1981) . The fact that the RS isomer did not provide the full range of effects observed with RAC might be a function of the administered dose, species, or differing rates of individual stereoisomer biotransformation. For example, if the RS isomer were cleared more rapidly than the RR isomer, it would not be expected to have the same potency as the RR isomer. Alternatively, if the SR and SS stereoisomers of RAC compete with the RS stereoisomer for biotransformation enzymes, the clearance of the RS stereoisomer in RAC might be slower than when administered singly.
The leanness-enhancing b-adrenergic agonist L-644,969 (Webster et al., 1995; is the RR stereoisomer of 6-amino-a-{[(1-methyl-3-phenylpropyl)amino]methyl}-3-pyridine methanol dihydrochloride . Presumably the most active stereoisomer of the possible four was produced for investigational purposes. The fact that the RR conformation of ractopamine was the most active at mimicking the effects of RAC is therefore consistent with other known leanness-enhancing agents.
In a broader sense, the results of this study indicate that data from studies investigating the mechanisms of b-adrenergic action at the cellular and receptor level could be misinterpreted because test systems (cells, cell membranes, tissues, etc.) have been tested with mixtures of stereoisomers. Structure activity studies with b-adrenergic agonists (Ruffolo, 1991) clearly indicate that the biological activities of phenethanolamine stereoisomers differ widely. When elucidating cellular and molecular mechanisms of action, simplicity is undermined when mixtures of stereoisomers are used because competition among stereoisomers may be occurring at receptors, target enzymes, or binding proteins (Ariëns, 1984) . This competition may result in ambiguous data that are difficult to interpret. For example, receptor affinities, binding constants, rates of enzyme activation, and other measures may represent the action of only one isomer in a mix, and that isomer may have to compete with others for the binding site. When delineating mechanisms of drug action, the physiological response(s) to the "whole" drug must be considered, but an understanding of the collective actions of individual components (i.e., stereoisomers or metabolites) is critical to a mechanistic understanding of the drug. That is, the physiological effects of individual stereoisomers and metabolites must each be considered in the context of the overall action of the drug. The use of isomerically pure compounds might simplify the process of elucidating the unknown cellular and molecular mechanisms of action of b-adrenergic leanness-enhancing agents.
Implications
This study provides evidence that the RR stereoisomer of ractopamine is the leanness-enhancing isomer of ractopamine HCl. This finding is consistent with scientific evidence that the levorotatory stereoisomers of direct-acting b-adrenergic agonists are responsible for their biological effects. Studies probing the mechanisms of b-adrenergic agonistinduced "repartitioning" might be simplified by the use of isomerically pure compounds.
